FDA staff report says data shows Pfizer's Covid treatment Paxlovid is effective in high-risk adults
Publishing timestamp: 2023-03-14 17:23:53
Summary
FDA staff have concluded that Pfizer's clinical trial results on its Covid antiviral pill Paxlovid support the drug's use in adults at high risk of progressing to severe disease. The external advisors on the agency's Antimicrobial Drugs Advisory Committee will discuss whether to recommend full approval of Paxlovid for treatment of mild to moderate Covid in high-risk adults. The meeting comes as companies like Pfizer brace for a drop in sales of Covid vaccines and treatments that led to record revenues earlier in the pandemic. Sales of Paxlovid jumped to $18.9 billion in 2022, but the company expects that revenue to drop 58% to $8 billion this year.
Sentiment: NEUTRAL
Keywords: pfizer inc, health care industry, business news, biotechnology, united states, pharmaceuticals, moderna inc, breaking news: business, breaking news, biotech and pharmaceuticals,